Last update Jan. 29, 2017

卡立普多

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Skeletal muscle relaxant with sedative effects on the central nervous system. It is metabolized to meprobamate.
Indicated on low back pain.

It is excreted into breast milk in a clinically non-significant amount (Nordeng 2001, Bailey 2002, Briggs 2008) without problems being observed on infants whose mothers were receiving this medication, (Nordeng 2001), except for a mild sedation with higher maternal drug doses (Briggs 2008) .
Plasma levels in the infant were undetectable (Briggs 2008).

Carisoprodol use increases the risk of abuse and addictive behavior, intoxication and possible psychomotor impairment (Bailey 2002, EMA 2007) being such a reason to be withdrawn from the market in some countries. The European Medicines Agency (EMA) has recommended to withhold authorizations for marketing of medicines that contains Carisoprodol (EMA 2007, Reeves 2012, Bramases 2012).

If administered during breastfeeding, it is advisable to use a minimum effective dose and monitor a possible sedation on the infant and an inadequate milk production (Sachs 2013).

Alternatives

  • Ibuprofen ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Paracetamol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

卡立普多 is Carisoprodol in Chinese.

Is written in other languages:

卡立普多 is also known as

Group

卡立普多 belongs to this group or family:

Tradenames

Main tradenames from several countries containing 卡立普多 in its composition:

  • Algiseda™. Contains other elements than 卡立普多 in its composition
  • Dolaren™. Contains other elements than 卡立普多 in its composition
  • Dorsal™. Contains other elements than 卡立普多 in its composition
  • Flexagil
  • Miorelax
  • Naxodol (Mexico)™. Contains other elements than 卡立普多 in its composition
  • Sodol Compound™. Contains other elements than 卡立普多 in its composition
  • Soma
  • Somacid
  • Somadril

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 260 daltons
Protein Binding 60 %
Tmax 4 hours
8 hours
M/P ratio 2 - 4 -
Theoretical Dose 1.9 mg/Kg/d
Relative Dose 5.4 %

References

  1. Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013 Sep;132(3):e796-809. Abstract Full text (link to original source) Full text (in our servers)
  2. Meda. Carisoprodol. Drug Summary. 2013 Full text (in our servers)
  3. Bramness JG, Furu K, Skurtveit S, Engeland A. Effect of the market withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. Clin Pharmacol Ther. 2012 Abstract
  4. Reeves RR, Burke RS, Kose S. Carisoprodol: update on abuse potential and legal status. South Med J. 2012 Abstract
  5. Briggs GG, Ambrose PJ, Nageotte MP, Padilla G. High-dose carisoprodol during pregnancy and lactation. Ann Pharmacother. 2008 Abstract
  6. EMA. European Medicines Agency recommends suspension of marketing authorisations for carisoprodol-containing medicinal products. Press office. 2007 Full text (in our servers)
  7. EMA. Conclusiones científicas y motivos de la suspensión de las autorizaciones de comercialización presentados por la EMEA. Anexo II. 2007 Full text (in our servers)
  8. AEMPS. Carisoprodol. Ficha técnica. 2005 Full text (in our servers)
  9. Bailey DN, Briggs JR. Carisoprodol: an unrecognized drug of abuse. Am J Clin Pathol. 2002 Abstract
  10. Nordeng H, Zahlsen K, Spigset O. Transfer of carisoprodol to breast milk. Ther Drug Monit. 2001 Abstract

Total visits

1,393

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM